论文部分内容阅读
目的:对海洋放线菌NZ1203进行菌种鉴定,并对其抗肿瘤代谢产物进行初步研究。方法:通过形态学观察和16S rDNA基因序列分析,鉴定菌株;用石油醚、乙酸乙酯及正丁醇对其发酵液依次进行萃取,并且通过抑菌实验和抗肿瘤实验对其发酵萃取物的活性进行初步研究。结果:通过菌株鉴定,将放线菌NZ1203归属于极暗黄链霉菌属(Streptomyces fulvissimus);乙酸乙酯提取物和正丁醇提取物具有较强的抑菌作用和良好的抗肿瘤效果,且正丁醇相优于乙酸乙酯相,石油醚相无抑菌效果。结论:海洋放线菌NZ1203为极暗黄链霉菌属,其代谢产物抑菌和抗肿瘤作用效果明显,可进一步进行分离鉴定,获得单体代谢产物,为进一步药物开发提供前期研究和物质基础。
Objective: To identify marine actinomycete strain NZ1203 and study its anti-tumor metabolites. Methods: The strains were identified by morphological observation and 16S rDNA gene sequence analysis. The fermentation broths were extracted by petroleum ether, ethyl acetate and n-butanol, and the fermentation broth was extracted by antibacterial and antitumor assays Activity preliminary study. Results: Actinomyces strain NZ1203 belonged to Streptomyces fulvissimus through identification of strains. Ethyl acetate extract and n-butanol extract had strong antibacterial activity and anti-tumor effect, and positive Butanol phase is better than ethyl acetate phase, petroleum ether phase has no antibacterial effect. CONCLUSION: Actinomycete strain NZ1203 is an extremely dark yellow Streptomyces and its metabolites have obvious bacteriostasis and anti-tumor effects. They can be further isolated and identified to obtain single metabolites, providing preliminary research and material basis for further drug development.